Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of March 2026, with the report dated March 12, 2026. The Company, a foreign private issuer based in Tel Aviv, Israel, primarily reports on a significant strategic transaction executed by its controlling subsidiary, NeuroTheraLabs Inc. ("NeuroThera"), in which SciSparc holds approximately 75% interest.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the reporting period. Instead, it details the financial structure of a proposed acquisition:
- Acquisition Target: NeuroThera agreed to acquire 56,375 ordinary shares of CliniQuantum Ltd., representing approximately 54.01% of CliniQuantum's issued and outstanding shares on a fully diluted basis.
- Consideration Value: NeuroThera will issue 56,600,000 common shares to selling shareholders, valued at approximately $9,459,954.20 based on the 20-day volume-weighted average trading price on the TSX Venture Exchange.
- Contingent Consideration (Earn-Out): Up to $2,500,000 in aggregate, payable in cash or shares over three years. This includes up to $1,500,000 for patent filing milestones and up to $1,000,000 based on 7.0% of future fundraising proceeds.
- Transaction Costs: NeuroThera will issue 2,829,999 common shares to arm's length finders as fees.
- Ownership Impact: SciSparc's ownership stake in NeuroThera is expected to dilute from approximately 75% to 43.86% post-closing.
Material Changes and Strategic Developments
The primary material change is the definitive agreement to acquire a majority stake in CliniQuantum, an innovator in quantum-based clinical trials. Additionally, on March 12, 2026, NeuroThera announced the publication of an international patent in collaboration with Clearmind Medicine for a novel therapy targeting weight loss and fatty liver disease. The filing notes that the Company's effective control over NeuroThera will decrease significantly following the transaction closing.
Outlook, Risks, and Contingencies
Closing Conditions and Timing: The transaction is expected to close within 30 days of submitting an application for an Israeli tax ruling, with an anticipated closing date on or about March 31, 2026. Closing is subject to customary conditions and the satisfaction or waiver of the tax ruling requirement.
Risks and Uncertainties: The filing includes a cautionary note regarding forward-looking statements. Key risks include the possibility that the transaction may not close as expected or at all, and that the conditions for Earn-Out payments may not be met. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the status of the Israeli tax ruling application, as it is a condition precedent to closing.
- Confirm the exact dilution impact on SciSparc's ownership percentage in NeuroThera post-closing.
- Monitor the achievement of CliniQuantum's patent filing milestones to assess potential Earn-Out liabilities.
- Review the specific terms of the collaboration with Clearmind Medicine regarding the new weight loss and fatty liver therapy patent.
- Assess the impact of the share issuance on NeuroThera's existing shareholder base and trading volume on the TSX Venture Exchange.